Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism.

The American journal of psychiatry - 1 Apr 2014

Kranzler Henry R, Covault Jonathan, Feinn Richard, Armeli Stephen, Tennen Howard, Arias Albert J, Gelernter Joel, Pond Timothy, Oncken Cheryl, Kampman Kyle M

Abstract excerpt

OBJECTIVE: Topiramate has been shown to reduce drinking and heavy drinking in individuals with alcohol dependence whose goal was to stop drinking. The authors evaluated the efficacy and tolerability of topiramate in heavy drinkers whose treatment goal was to reduce drinking to safe levels. METHOD: A total of 138 individuals (62.3% men) were randomly assigned to receive 12 weeks of treatment with topiramate...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alcoholism
Share to Double-Blind Method

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fructose

Share to Neurotransmitter Receptor Influence on Behavior

Share to Polymorphism, Single Nucleotide

Share to Receptors, Kainic Acid

Share to Substance Abuse Treatment and Outcomes

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 24525690
DOI: 10.1176/appi.ajp.2013.13081014
PMCID: PMC3997125

Genes

GRIK1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism.PMID 24525690Read ↗

Posttreatment effects of topiramate treatment for heavy drinking.Semantic proximity Read ↗

Combined analysis of the moderating effect of a GRIK1 polymorphism on the effects of topiramate for treating alcohol use disorder.Semantic proximity Read ↗

GRIK1 genotype moderates topiramate's effects on daily drinking level, expectations of alcohol's positive effects and desire to drink.Semantic proximity Read ↗

A preliminary pharmacogenetic investigation of adverse events from topiramate in heavy drinkers.Semantic proximity Read ↗

Topiramate's reduction of body mass index in heavy drinkers: lack of moderation by a GRIK1 polymorphism.Semantic proximity Read ↗

An intensive longitudinal examination of topiramate treatment for alcohol use disorder: a secondary analysis of data from a randomized controlled trial.Semantic proximity Read ↗

Topiramate Versus Naltrexone for Alcohol Use Disorder: A Genotype-Stratified Double-Blind Randomized Controlled Trial.Semantic proximity Read ↗

Balancing risk and benefit in heavy drinkers treated with topiramate: implications for personalized care.Semantic proximity Read ↗

GRIK1 genotype and daily expectations of alcohol's positive effects moderate the reduction of heavy drinking by topiramate.Semantic proximity Read ↗

Self-efficacy mediates the effects of topiramate and GRIK1 genotype on drinking.Semantic proximity Read ↗

Molecular correlates of topiramate and <i>GRIK1</i> rs2832407 genotype in pluripotent stem cell-derived neural culturesSemantic proximity Read ↗

Molecular Correlates of Topiramate and GRIK1 rs2832407 Genotype in Pluripotent Stem Cell-Derived Neural Cultures.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.